US Patent Issued to Jiangsu Hengrui Medicine, SHANGHAI HENGRUI PHARMACEUTICAL on Feb. 24 for "Substituted morpholines as ATR kinase inhibitors" (Chinese Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,488, issued on Feb. 24, was assigned to Jiangsu Hengrui Medicine Co. Ltd. (Lianyungang, China) and SHANGHAI HENGRUI PHARMACEUTICAL Co. LTD. (Shanghai).

"Substituted morpholines as ATR kinase inhibitors" was invented by Xin Li (Shanghai), Huaide Dong (Shanghai), Dongdong Bai (Shanghai), Feng He (Shanghai) and Weikang Tao (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is a pyrazolo-heteroaryl derivative, a preparation method therefor, and medical use thereof. In particular, the present invention relates to a pyrazolo-heteroaryl derivative as shown in the general formula (I), a preparation method therefor, a pharmaceutical compositi...